“It is no coincidence that the industry announced a new initiative today,” Health and Human Services Secretary Alex Azar said in a speech at the National Academy of Medicine. “Placing information on a website is not the same as putting it right in an ad.” Azar had said earlier that the proposal to set up the sites was a “small step in the right direction.”

The industry group, the Pharmaceutical Research and Manufacturers of America, said any U.S. requirement to disclose list prices in advertising could violate the First Amendment because of restrictions on “compelled speech.”

“Putting a list price in isolation in an ad itself is very confusing, misleading and lacks appropriate context,” said Steve Ubl, chief executive officer of the Pharmaceutical Research and Manufacturers of America, during a conference call on Monday.

The pricing requirement was first proposed in May when President Donald Trump released a blueprint to bring down drug prices. Azar, a former Eli Lilly & Co. executive, said that the administration is willing to go further.

“We will go beyond the four corners of the blueprint if we need to,” he said. “Any ideas that could bring down costs while respecting innovation and patient choice are on the table.”

Drugmakers have argued that disclosing list prices in ads could be misleading because of rebates and insurance co-pays that can affect how much of their own money people actually spend. Critics of the industry say list prices are relevant because many Americans have co-insurance and high-deductible plans that force them to shoulder a significant portion of a drug's price.

What's behind the high cost of drugs?

• Pharma profits, drug prices both soaring
• Hospital drug shortages send prices soaring
• Curbing specialty drug spending: Where to start?

Copyright 2018 Bloomberg. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.